Tao Su

Tao Su

Auto-generated profile, based on publicly available information

Tao Su

Laboratory of Clinical Proteomics and Metabolomics Institutes for Systems Genetics Frontiers Science Center for Disease‐related Molecular Network West China Hospital Sichuan University Chengdu China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YZYi Zhong
Yi Zhong
TSTao Su
Tao Su
QSQiuxiao Shi
Qiuxiao Shi
YFYanru Feng
Yanru Feng
ZTZe Tao
Ze Tao
Hao YangHao Yang
Hao Yang
Background: Nanoparticles exhibit great promise for improving the solubility and tissue-specific distribution of chemotherapeutic agents; however, the passive and highly variable enhanced permeability and retention (EPR) effects observed in tumors frequently leads to insufficient delivery of nanodrugs into tumors. The tumor-penetrating peptide iRGD can actively enhance tumor-selective delivery of nanoparticles into tumors by binding to integrin and interacting with tissue-penetrating receptor neuropilin-1. Materials and methods: To improve colorectal cancer treatment, in this study, we prepared a paclitaxel (PTX)-loaded PLGA nanoparticle (PLGA-PTX) and evaluated its tumor-targeting and antitumor activity by co-administration with iRGD. Results: Compared to free PTX, encapsulated PTX retained preferential cytotoxicity toward various colorectal cancer cells while effectively sparing healthy cells. PLGA-PTX treatment resulted in cell cycle arrest at the G2/M phase and apoptosis, leading to inhibition of cancer cell migration and invasion. PLGA-PTX combined with iRGD displayed little enhancement of cytotoxicity in vitro. Despite this, iRGD receptors integrin and neuropilin-1 were found to be primarily overexpressed on abundant tumor vessels in mice bearing colorectal tumors. Consequently, co-administration of nanoparticles with iRGD promoted the selective delivery of nanoparticles into tumor tissues in vivo. Additionally, the combined regimen enhanced the antitumor effects compared to those of each individual reagent. Conclusion: Our findings suggest that PLGA nanoparticles combined with the iRGD peptide provide a promising drug delivery strategy for facilitating active drug accumulation into tumors, given that iRGD receptors are overexpressed on tumor vessels. This co-administration system lacking covalent conjugation provides a more convenient means to combine various therapeutic agents with iRGD to achieve personalized nanotherapy.

10 February 2023 in Biomaterials
Verified
Journal Article
Closed access
Hao YangHao Yang
Hao Yang
HLHeng Li
Heng Li
FYFen Yang
Fen Yang
ZTZe Tao
Ze Tao
QSQiuxiao Shi
Qiuxiao Shi
XLXiaofeng Lu
Xiaofeng Lu

6 December 2021 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
TSTao Su
Tao Su
YZYi Zhong
Yi Zhong
WZWeibiao Zeng
Weibiao Zeng
Yong ZhangYong Zhang
Yong Zhang
SWShisheng Wang
Shisheng Wang
MGMeng Gong
Meng Gong